Meeting of the National Clinical Care Commission, 61633-61634 [2019-24636]

Download as PDF Federal Register / Vol. 84, No. 219 / Wednesday, November 13, 2019 / Notices responsibilities of states. Accordingly, the requirements of Executive Order 13132 do not apply to this notice. Executive Order 13771, titled ‘‘Reducing Regulation and Controlling Regulatory Costs,’’ was issued on January 30, 2017 (82 FR 9339, February 3, 2017). It has been determined that this notice is a transfer notice that does not impose more than de minimis costs and thus is not a regulatory action for the purposes of E.O. 13771. In accordance with the provisions of Executive Order 12866, this notice was reviewed by the Office of Management and Budget. V. Waiver of Proposed Rulemaking We ordinarily publish a notice of proposed rulemaking in the Federal Register and invite public comment prior to a rule taking effect in accordance with section 1871 of the Act and section 553(b) of the Administrative Procedure Act (APA). Section 1871(a)(2) of the Act provides that no rule, requirement, or other statement of policy (other than a national coverage determination) that establishes or changes a substantive legal standard governing the scope of benefits, the payment for services, or the eligibility of individuals, entities, or organizations to furnish or receive services or benefits under Medicare shall take effect unless it is promulgated through notice and comment rulemaking. Unless there is a statutory exception, section 1871(b)(1) of the Act generally requires the Secretary of the Department of Health and Human Services (the Secretary) to provide for notice of a proposed rule in the Federal Register and provide a period of not less than 60 days for public comment before establishing or changing a substantive legal standard regarding the matters enumerated by the statute. Similarly, under 5 U.S.C. 553(b) of the APA, the agency is required to publish a notice of proposed rulemaking in the Federal Register before a substantive rule takes effect. Section 553(d) of the APA and section 1871(e)(1)(B)(i) of the Act usually require a 30-day delay in effective date after issuance or publication of a rule, subject to exceptions. Sections 553(b)(B) and 553(d)(3) of the APA provide for exceptions from the advance notice and comment requirement and the delay in effective date requirements. Sections 1871(b)(2)(C) and 1871(e)(1)(B)(ii) of the Act also provide exceptions from the notice and 60-day comment period and the 30-day delay in effective date. Section 553(b)(B) of the APA and section 1871(b)(2)(C) of the Act expressly authorize an agency to dispense with notice and comment VerDate Sep<11>2014 17:23 Nov 12, 2019 Jkt 250001 rulemaking for good cause if the agency makes a finding that notice and comment procedures are impracticable, unnecessary, or contrary to the public interest. The annual updated amounts for the Part B monthly actuarial rates for aged and disabled beneficiaries, the Part B premium, and Part B deductible set forth in this notice do not establish or change a substantive legal standard regarding the matters enumerated by the statute or constitute a substantive rule which would be subject to the notice requirements in section 553(b) of the APA. However, to the extent that an opportunity for public notice and comment could be construed as required for this notice, we find good cause to waive this requirement. Section 1839 of the Act requires the Secretary to determine the monthly actuarial rates for aged and disabled beneficiaries as well as the monthly Part B premium (including the incomerelated monthly adjustment amounts to be paid by beneficiaries with modified adjusted gross income above certain threshold amounts) for each calendar year in accordance with the statutory formulae, in September preceding the year to which they will apply. Further, the statute requires that the agency promulgate the Part B premium amount, in September preceding the year to which it will apply, and include a public statement setting forth the actuarial assumptions and bases employed by the Secretary in arriving at the amount of an adequate actuarial rate for enrollees age 65 and older. We include the Part B annual deductible, which is established pursuant to a specific formula described in section 1833(b) of the Act, because the determination of the amount is directly linked to the rate of increase in actuarial rate under section 1839(a)(1) of the Act. We have calculated the monthly actuarial rates for aged and disabled beneficiaries, the Part B deductible, and the monthly Part B premium as directed by the statute; the statute establishes both when the monthly actuarial rates for aged and disabled beneficiaries and the monthly Part B premium must be published and the information that the Secretary must factor into those amounts, so we do not have any discretion in that regard. We find notice and comment procedures to be unnecessary for this notice and we find good cause to waive such procedures under section 553(b)(B) of the APA and section 1871(b)(2)(C) of the Act, if such procedures may be construed to be required at all. Through this notice, we are simply notifying the public of the updates to the monthly actuarial rates PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 61633 for aged and disabled beneficiaries, the Part B deductible, as well as the monthly Part B premium amounts and the income-related monthly adjustment amounts to be paid by certain beneficiaries, in accordance with the statute, for CY 2020. As such, we also note that even if notice and comment procedures were required for this notice, for the previously stated reason, we would find good cause to waive the delay in effective date of the notice, as additional delay would be contrary to the public interest under section 1871(e)(1)(B)(ii) of the Act. Publication of this notice is consistent with section 1839 of the Act, and we believe that any potential delay in the effective date of the notice, if such delay were required at all, could cause unnecessary confusion both for the agency and Medicare beneficiaries. Dated: October 24, 2019. Seema Verma, Administrator, Centers for Medicare & Medicaid Services. Dated: October 28, 2019. Alex M. Azar II, Secretary, Department of Health and Human Services. [FR Doc. 2019–24440 Filed 11–8–19; 4:15 pm] BILLING CODE 4120–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the National Clinical Care Commission Office of Disease Prevention and Health Promotion, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: The National Clinical Care Commission (the Commission) will conduct its fifth meeting on Friday, November 22, 2019. The Commission is charged to evaluate and make recommendations to the U.S. Department of Health and Human Services (HHS) Secretary and Congress regarding improvements to the coordination and leveraging of federal programs related to awareness and clinical care for complex metabolic or autoimmune diseases that result from issues related to insulin that represent a significant disease burden in the United States, which may include complications due to such diseases. DATES: The meeting will take place on Friday, November 22, 2019, from 8:00 a.m. to approximately 4:00 p.m. Eastern Time (ET). SUMMARY: E:\FR\FM\13NON1.SGM 13NON1 61634 Federal Register / Vol. 84, No. 219 / Wednesday, November 13, 2019 / Notices The public meeting will be held at the Bethesda North Marriott Hotel and Conference Center, 5701 Marinelli Rd., Rockville, MD 20852; 301–822–9200. The meeting will also be held online via webcast. To pre-register to attend the meeting, please visit the registration website at https:// events.kauffmaninc.com/events/nccc5/. ADDRESSES: FOR FURTHER INFORMATION CONTACT: Linda Harris, Designated Federal Officer, National Clinical Care Commission, U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health, Office of Disease Prevention and Health Promotion, 1101 Wootton Parkway, Suite 420, Rockville, MD 20852. Email: OHQ@hhs.gov. The National Clinical Care Commission Act (Pub. L. 115–80) requires the HHS Secretary to establish the National Clinical Care Commission. The Commission consists of representatives of specific federal agencies and nonfederal individuals and entities who represent diverse disciplines and views. The Commission will evaluate and make recommendations to the HHS Secretary and Congress regarding improvements to the coordination and leveraging of federal programs related to awareness and clinical care for complex metabolic or autoimmune diseases that result from issues related to insulin that represent a significant disease burden in the United States, which may include complications due to such diseases. During this fifth meeting, the Commission will hear from informants from selected federal agencies about programs related to diabetes prevention, treatment and discuss potential topics for the Commission’s final report. The final meeting agenda will be available prior to the meeting at https:// health.gov/hcq/national-clinical-carecommission.asp. Public Participation at Meeting: The Commission invites public comment on issues related to the Commission’s charge either in-person at the meeting or in writing. In-person attendees who plan to provide oral comments at the Commission meeting during a designated time must submit their comments to OHQ@hhs.gov on or before November 15, 2019 and must check-in on-site. To accommodate as many individuals as possible, the time for each comment will be limited to three minutes. If more requests are received than can be accommodated, speakers will be randomly selected. The nature of the comments will not be considered in making this selection. SUPPLEMENTARY INFORMATION: VerDate Sep<11>2014 17:23 Nov 12, 2019 Jkt 250001 Written comments are welcome throughout the entire development process of the Commission’s recommendation and may be emailed to OHQ@hhs.gov, or by mail to the following address: Public Commentary, National Clinical Care Commission, 1101 Wootton Parkway, Suite 420, Rockville, MD 20852. Written comments should not exceed three pages in length. Individuals who need special assistance, such as sign language interpretation or other reasonable accommodations, should indicate the special accommodation when registering online or by notifying Jennifer Gillissen at jennifer.gillissen@ kauffmaninc.com by November 15. Authority: The National Clinical Care Commission is required under the National Clinical Care Commission Act (Pub. L. 115–80). The Commission is governed by provisions of the Federal Advisory Committee Act (FACA), Public Law 92–463, as amended (5 U.S.C., App.) which sets forth standards for the formation and use of federal advisory committees. Dated: November 5, 2019. Donald Wright, Deputy Assistant Secretary for Health, Disease Prevention and Health Promotion. [FR Doc. 2019–24636 Filed 11–12–19; 8:45 am] BILLING CODE 4150–32–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Cancer Health Disparities. Date: December 5–6, 2019. Time: 7:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW, Washington, DC 20015. Contact Person: Nywana Sizemore, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6204, MSC 7804, Bethesda, MD 20892, (301) 435– 1718, sizemoren@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cardiovascular Sciences. Date: December 5–6, 2019. Time: 8:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Kimm Hamann, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4118A, MSC 7814, Bethesda, MD 20892, (301) 435– 5575, hamannkj@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: AIDS and AIDS Related Research. Date: December 5–6, 2019. Time: 9:30 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Jingsheng Tuo, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5207, Bethesda, MD 20892, (301) 451–8754, tuoj@ nei.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Psycho/Neuropathology Lifespan Development. Date: December 5, 2019. Time: 11:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Elia E. Ortenberg, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3108, Bethesda, MD 20892, (301) 827–7189, femiaee@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Neurodegeneration, Myelination and Glia. Date: December 5, 2019. Time: 11:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Mary Custer, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4148, MSC 7850, Bethesda, MD 20892, (301) 435– 1164, custerm@csr.nih.gov. E:\FR\FM\13NON1.SGM 13NON1

Agencies

[Federal Register Volume 84, Number 219 (Wednesday, November 13, 2019)]
[Notices]
[Pages 61633-61634]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-24636]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the National Clinical Care Commission

AGENCY: Office of Disease Prevention and Health Promotion, Office of 
the Assistant Secretary for Health, Office of the Secretary, Department 
of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Clinical Care Commission (the Commission) will 
conduct its fifth meeting on Friday, November 22, 2019. The Commission 
is charged to evaluate and make recommendations to the U.S. Department 
of Health and Human Services (HHS) Secretary and Congress regarding 
improvements to the coordination and leveraging of federal programs 
related to awareness and clinical care for complex metabolic or 
autoimmune diseases that result from issues related to insulin that 
represent a significant disease burden in the United States, which may 
include complications due to such diseases.

DATES: The meeting will take place on Friday, November 22, 2019, from 
8:00 a.m. to approximately 4:00 p.m. Eastern Time (ET).

[[Page 61634]]


ADDRESSES: The public meeting will be held at the Bethesda North 
Marriott Hotel and Conference Center, 5701 Marinelli Rd., Rockville, MD 
20852; 301-822-9200. The meeting will also be held online via webcast. 
To pre-register to attend the meeting, please visit the registration 
website at https://events.kauffmaninc.com/events/nccc5/.

FOR FURTHER INFORMATION CONTACT: Linda Harris, Designated Federal 
Officer, National Clinical Care Commission, U.S. Department of Health 
and Human Services, Office of the Assistant Secretary for Health, 
Office of Disease Prevention and Health Promotion, 1101 Wootton 
Parkway, Suite 420, Rockville, MD 20852. Email: [email protected].

SUPPLEMENTARY INFORMATION: The National Clinical Care Commission Act 
(Pub. L. 115-80) requires the HHS Secretary to establish the National 
Clinical Care Commission. The Commission consists of representatives of 
specific federal agencies and non-federal individuals and entities who 
represent diverse disciplines and views. The Commission will evaluate 
and make recommendations to the HHS Secretary and Congress regarding 
improvements to the coordination and leveraging of federal programs 
related to awareness and clinical care for complex metabolic or 
autoimmune diseases that result from issues related to insulin that 
represent a significant disease burden in the United States, which may 
include complications due to such diseases. During this fifth meeting, 
the Commission will hear from informants from selected federal agencies 
about programs related to diabetes prevention, treatment and discuss 
potential topics for the Commission's final report. The final meeting 
agenda will be available prior to the meeting at https://health.gov/hcq/national-clinical-care-commission.asp.
    Public Participation at Meeting: The Commission invites public 
comment on issues related to the Commission's charge either in-person 
at the meeting or in writing. In-person attendees who plan to provide 
oral comments at the Commission meeting during a designated time must 
submit their comments to [email protected] on or before November 15, 2019 and 
must check-in on-site. To accommodate as many individuals as possible, 
the time for each comment will be limited to three minutes. If more 
requests are received than can be accommodated, speakers will be 
randomly selected. The nature of the comments will not be considered in 
making this selection.
    Written comments are welcome throughout the entire development 
process of the Commission's recommendation and may be emailed to 
[email protected], or by mail to the following address: Public Commentary, 
National Clinical Care Commission, 1101 Wootton Parkway, Suite 420, 
Rockville, MD 20852. Written comments should not exceed three pages in 
length. Individuals who need special assistance, such as sign language 
interpretation or other reasonable accommodations, should indicate the 
special accommodation when registering online or by notifying Jennifer 
Gillissen at [email protected] by November 15.
    Authority: The National Clinical Care Commission is required under 
the National Clinical Care Commission Act (Pub. L. 115-80). The 
Commission is governed by provisions of the Federal Advisory Committee 
Act (FACA), Public Law 92-463, as amended (5 U.S.C., App.) which sets 
forth standards for the formation and use of federal advisory 
committees.

    Dated: November 5, 2019.
Donald Wright,
Deputy Assistant Secretary for Health, Disease Prevention and Health 
Promotion.
[FR Doc. 2019-24636 Filed 11-12-19; 8:45 am]
BILLING CODE 4150-32-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.